February 20, 2015 — The Mevion S250 proton therapy system has become the first proton therapy system to receive a medical device license from Health Canada, the federal department responsible for public health, and is now approved to be installed at cancer facilities across the country.
Proton therapy targets cancer cells more precisely than traditional photon radiation treatment and results in less damage to surrounding healthy tissue and organs. Because of this, it is ideal for treating pediatric patients and adult patients with cancers in sensitive locations, such as near the brain, spine, heart, and lungs.
The Mevion S250 offers the same capabilities of significantly larger and more expensive proton therapy systems but with a much smaller footprint, improved reliability, more efficient patient access and dramatically lower capital and operational costs.
According to the Canadian Cancer Society, an estimated 97,700 men and 93,600 women were diagnosed with cancer in Canada in 2014. Of these new cases, many were types of cancer that are frequently treated with proton therapy, including lung cancer (13.9 percent of new cancer cases in men, 13.3 percent in women), cancer in the brain or central nervous system (1.7 percent of new cancer cases in men, 1.3 percent in women), prostate cancer (24.1 percent of new cancer cases in men) and breast cancer (26.1 percent of new cancer cases in women).
For more information: www.mevion.com
March 28, 2024 
